RxDoctor Payments Data

Ashley Zurcher, NP

Gerontology · Albuquerque, NMNPI 1023573359

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,450 of the $1,965 with a category attached, or 73.8%. AstraZeneca accounts for 93.5% of it on its own, with 4 other manufacturers making up the rest. Among gerontology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,965in general payments, 2019–2025

Across 20 payments — averaging $98.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Fresenius USA Marketing, Inc.$54
  • Otsuka America Pharmaceutical, Inc.$41
  • Vifor Pharma, Inc.$19
  • OPKO Pharmaceuticals, LLC$14

What the payments were for

  • Speaking & faculty fees$1,45074%
  • Food & beverage$51526%

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,965 in reported general payments places this provider in the 90th percentile of 20 gerontology providers in New Mexico.

See all gerontology providers in New Mexico

Medicare billing

Part B allowed, 2024
$218,782
Medicare patients
306
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$24,663
TrulicityDulaglutide38$23,233
XareltoRivaroxaban67$18,605
TradjentaLinagliptin31$8,025
Pregabalin118$6,821
Fiasp FlextouchInsulin Aspart (Niacinamide)23$6,585
Incruse ElliptaUmeclidinium Bromide26$5,680
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$4,902
Memantine Hcl68$4,556
Tresiba Flextouch U-100Insulin Degludec11$4,470
Atorvastatin Calcium170$4,144
Gabapentin175$4,035
Levetiracetam50$4,010
FarxigaDapagliflozin Propanediol13$3,844
Levothyroxine Sodium342$3,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,838$3,84413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 gerontology providers in New Mexico.

Other gerontology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →